反应详情

Following the procedure as described in EXAMPLE 44, making non-critical variations to replace di-tert-butyl [5-(5-chloro-2-{4-[(2,4-dimethoxybenzyl)(1,2,4-thiadiazol-5-yl)sulfamoyl]-2,5-difluorophenoxy}phenyl)-1,2-benzoxazol-3-yl]imidodicarbonate with 4-(4-chloro-2-(2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenoxy)-N-(2,4-dimethoxybenzyl)-3-fluoro-N-(pyrimidin-2-yl)benzenesulfonamide, 4-(4-chloro-2-(2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenoxy)-3-fluoro-N-(pyrimidin-2-yl)benzenesulfonamide was obtained a beige solid in 50% yield over two steps (0.054 g): 1H NMR (300 MHz, DMSO-d6) δ11.93 (br s, 1H), 11.69 (s, 1H), 8.50 (d, J=2.9 Hz, 2H), 7.83 (d, J=9.8 Hz, 1H), 7.66 (d, J=8.0 Hz, 1H), 7.59 (s, 1H), 7.49 (d, J=7.7 Hz, 1H), 7.29-7.01 (m, 6H); MS (ES+) m/z 512.8 (M+1), 514.8 (M+1).